Corona crisis has limited impact on infant participation in National Immunisation Programme Nearly all infants in the Netherlands are still participating in the National Immunisation Programme.
Initial results on how COVID-19 spreads within Dutch families The novel coronavirus is primarily spread amongst adults who are about the same age. Within families, the virus is mainly transmitted from adults to children.
Risks of chemical substances to human health and the environment RIVM is developing methods to identify new and emerging risks of chemical substances to workers, consumers and the environment.
Use of other needles in Dutch Immunisation Programme as a precaution As a result of the EenVandaag broadcast regarding the safety of injection needles, and after consultation with the Dutch Inspection for Health Care (IGZ), RIVM advises against the use of needles so
New insights on ammonia emissions Calculated ammonia emissions in the Netherlands are still declining. However, emissions overall are greater than previously assumed.
Harmful substances in e-cigarettes assessed While e-cigarettes are less harmful to health than tobacco cigarettes, the vapour from an e-cigarette contains substances and chemical impurities in concentrations that could be detrimental to heal
Reduced-sodium lunches result in decreased daily dietary sodium intakes Consumption of reduced-sodium foods over a 3-week period was well accepted by uninformed participants in an experimental real-life canteen setting.
Utrecht Side Event International One Health Congress Scientists and policy makers from around the world will visit research institutes and companies in the field of Life Sciences in the Utrecht region on March 18th.
Big Data gives more insight into the health impacts of air pollution Long-term exposure to particulate air pollution and nitrogen dioxide has been found to be associated with total mortality and mortality from respiratory diseases and lung cancer in the Netherlands.
RIVM to research safe design for new nanoparticles RIVM will be working alongside a consortium of 23 international partners on a safe design for ‘new’ nanoparticles.